Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

McMaster University

$105,000.00

Mesenchymal stromal cell dysfunction as a driver of preleukemia

FY 2021-22

Summary
Leukemias originate from the accumulation of mutations within hematopoietic stem cells, which are responsible for replenishing blood and immune cells for the body. Mild, pre-leukemic mutations in these cells often arise in healthy individuals by chance, but usually do not cause disease because the affected stem cell is kept under control and retains its normal functions. Instead, progression to disease only occurs once these pre-leukemic cells are able to replicate themselves and take over a significant portion of the bone marrow. Our research studies pre-leukemic mutations in the SRSF2 gene, which are particularly aggressive and highly associated with disease. However, these mutations are unique in that they seem highly constrained by the environment. Our work proposes that mesenchymal stromal cells (MSCs), a population of supportive cells in the bone marrow, are responsible for controlling the outgrowth of SRSF2 mutants. Conversely, dysfunctional MSCs can unleash or even cooperate with these mutants, allowing them to rapidly outgrow healthy hematopoietic stem cells and take the first steps towards leukemia. By analyzing cellular changes in MSCs in aged individuals or individuals with leukemias, we hope to identify the key factors that allow them to support SRSF2 mutant stem cells. We will evaluate whether these factors can be used to predict which individuals are at risk of leukemia. We will also assess whether targeting these pathways via drugs can restore the function of MSCs and re-establish control over SRSF2 mutants before they can propagate, or even reverse the progress of SRSF2 mutants that are advancing towards leukemia. We hope that our findings will contribute to the ability to prevent leukemias before they develop.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
458583
Name
CHEN HE TIAN
Region
Ontario
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Mesenchymal stromal cell dysfunction as a driver of preleukemia
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Bone Marrow Microenvironment; Hematopoietic Stem Cells; Pre-Leukemia
Abstract
Leukemias originate from the accumulation of mutations within hematopoietic stem cells, which are responsible for replenishing blood and immune cells for the body. Mild, pre-leukemic mutations in these cells often arise in healthy individuals by chance, but usually do not cause disease because the affected stem cell is kept under control and retains its normal functions. Instead, progression to disease only occurs once these pre-leukemic cells are able to replicate themselves and take over a significant portion of the bone marrow. Our research studies pre-leukemic mutations in the SRSF2 gene, which are particularly aggressive and highly associated with disease. However, these mutations are unique in that they seem highly constrained by the environment. Our work proposes that mesenchymal stromal cells (MSCs), a population of supportive cells in the bone marrow, are responsible for controlling the outgrowth of SRSF2 mutants. Conversely, dysfunctional MSCs can unleash or even cooperate with these mutants, allowing them to rapidly outgrow healthy hematopoietic stem cells and take the first steps towards leukemia. By analyzing cellular changes in MSCs in aged individuals or individuals with leukemias, we hope to identify the key factors that allow them to support SRSF2 mutant stem cells. We will evaluate whether these factors can be used to predict which individuals are at risk of leukemia. We will also assess whether targeting these pathways via drugs can restore the function of MSCs and re-establish control over SRSF2 mutants before they can propagate, or even reverse the progress of SRSF2 mutants that are advancing towards leukemia. We hope that our findings will contribute to the ability to prevent leukemias before they develop.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
CHEN, HE TIAN
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
McMaster University - $105,000 Grant (2021-22) | Canada Spends